<DOC>
	<DOCNO>NCT02042911</DOCNO>
	<brief_summary>The purpose study investigate safety efficacy SyB L-0501 2-day intravenous infusion dose 100 mg/m2/day patient chronic lymphocytic leukemia .</brief_summary>
	<brief_title>Efficacy Safety Study SyB L-0501 Patients With Chronic Lymphocytic Leukemia</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<criteria>Inclusion Criteria Patients meeting follow criterion include study : 1 . Patients age 20 80 year ( time registration ) 2 . Patients provide write consent person participation study 3 . Patients Eastern Cooperative Oncology Group ( ECOG ) Performance Status ( PS ) 0 2 4 . Patients expect survive least 3 month 5 . Patients naive suitable fludarabine therapy 6 . Patients document chronic lymphocytic leukemia basis International Workshop Chronic Lymphocytic Leukaemia guideline ( IWCLL ) guideline : The presence ≥ 5000/mm3 monoclonal mature Blymphocytes peripheral blood ≤ 55 % atypical lymphocyte , prolymphocytelike cell , lymphoblasts prominent nucleolus For monoclonal mature Blymphocytes , least one Bcell specific differentiation antigen ( Cluster differentiation ( CD ) 19 , CD 20 , CD 23 ) CD 5 positive flow cytometry 7 . Patients Stage C stage B active disease base Binet stag system ( time registration ) Decision start treatment make upon IWCLL guideline criterion . Active disease define meet least one follow criterion . 1 . Progression and/or worsen anemia and/or thrombocytopenia cause decreased bone marrow function . 2 . Massive ( 6 cm leave costal margin ) progressive symptomatic splenomegaly 3 . Massive node ( ≥10 cm long diameter ) progressive symptomatic lymphadenopathy 4 . Progressive lymphocytosis increase &gt; 50 % 2month period , lymphocyte double time le 6 month 5 . Autoimmune anemia and/or thrombocytopenia poorly responsive corticosteroid standard therapy 6 . B symptom Weight loss &gt; 10 % within previous 6 month Fevers great 38.0° C 2 week without evidence infection Night sweat 8 . Patients 2 less regimen previous chemotherapy include antibody therapy . Corticosteroid monotherapy count . 9 . Patients adequately maintain organ function ( e.g. , bone marrow , heart , lung , liver , kidney function ) Neutrophil count : ≥ 1,000 /mm3 Aspartate aminotransferase ( AST ) Glutamic oxaloacetic transaminase ( GOT ) : ≤ 3.0 time upper limit normal range site Alanine aminotransferase ( ALT ) Glutamic pyruvic transaminase ( GPT ) : ≤ 3.0 time upper limit normal range site Total bilirubin : ≤ 1.5 time upper limit normal range site Serum creatinine : ≤ 1.5 time upper limit normal range site Partial pressure O2 ( PaO2 ) : ≥ 65 mmHg No abnormality require treatment detect ECG Left ventricular ejection fraction ( LVEF ) ( echocardiography ) : ≥ 55 % Patients fall one follow criterion exclude 1 . Patients without treatment le 4 week prior treatment . For patient treat antibody therapy underwent hematopoietic stem cell transplantation , 3 month prior treatment 2 . Patients enrol clinical study within 4 week registration study 3 . Patients receive allogeneic stem cell transplantation past 4 . Patients defective p53 ( 17p ) confirm chromosome analysis ( Fluorescence situ hybridization ( Fish ) method ) 5 . Patients clinically diagnose Richter 's syndrome 6 . Patients infiltration central nervous system ( CNS ) patient clinical symptom suspect infiltration CNS 7 . Patients multiple primary cancer patient history malignant tumor within past 5 year , except basal cell squamous cell skin cancer , carcinoma situ cervix gastrointestinal tract 8 . Patients serious bleed tendency ( e.g. , disseminate intravascular coagulation ( DIC ) ) 9 . Patients , confirm past , interstitial lung disease pulmonary fibrosis 10 . Patients , confirm past , autoimmune hemolytic anemia respond corticosteroid therapy 11 . Patients follow complication serious cardiac disease ( e.g. , myocardial infarction , ischemic heart disease , arrhythmia require treatment ) serious , active infection ( require intravenous administration antibiotic , antifungal drug , antiviral drug ) hepatic renal dysfunction accumulation pleural effusion , pericardial effusion , peritoneal effusion uncontrollable serious gastrointestinal disease , endocrine disorder , mental illness 12 . Patients receive SyB L0501 past 13 . Patients allergies mannitol 14 . Patients need cytokine preparation erythropoietin granulocyte colony stimulate factor ( GCSF ) blood transfusion registration study 15 . Patients positive HIV antibody Hepatitis C virus ( HCV ) antibody 16 . Patients positive Hepatitis B surface ( HBs ) antigen . Patients negative result also check Hepatitis B core ( HBc ) antibody HBs antibody . If either test result positive , measure Hepatitis B virus ( HBV ) DNA exclude patient result sensitivity 17 . Patients clinical symptom cytomegalovirus ( CMV ) infection , except asymptomatic patient CMV positive 18 . Patients pregnant , may possibly pregnant , lactate 19 . Patients agree practice contraception . Male : During investigational product administration 6 month final administration Female : During investigational product administration 4 month final administration 20 . Patients drug addiction , narcotic addiction , and/or alcohol dependency 21 . Patients otherwise judge investigator subinvestigator unsuitable inclusion study</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>